Literature DB >> 24217890

Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Zachary J Reitman1, Christopher J Pirozzi, Hai Yan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24217890      PMCID： PMC3888653          DOI： 10.1007/s00401-013-1207-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  14 in total

1.  TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas.

Authors:  Hideyuki Arita; Yoshitaka Narita; Hirokazu Takami; Shintaro Fukushima; Yuko Matsushita; Akihiko Yoshida; Yasuji Miyakita; Makoto Ohno; Soichiro Shibui; Koichi Ichimura
Journal:  Acta Neuropathol       Date:  2013-10-31       Impact factor: 17.088

2.  Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.

Authors:  Jian Hu; Soyoon Sarah Hwang; Marc Liesa; Boyi Gan; Ergun Sahin; Mariela Jaskelioff; Zhihu Ding; Haoqiang Ying; Adam T Boutin; Hailei Zhang; Shawn Johnson; Elena Ivanova; Maria Kost-Alimova; Alexei Protopopov; Yaoqi Alan Wang; Orian S Shirihai; Lynda Chin; Ronald A DePinho
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

3.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

4.  A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

Authors:  Jeremy D Henson; Jonathan A Hannay; Stanley W McCarthy; Janice A Royds; Thomas R Yeager; Robert A Robinson; Stephen B Wharton; David A Jellinek; Susan M Arbuckle; Jinyoung Yoo; Bruce G Robinson; Diana L Learoyd; Paul D Stalley; S Fiona Bonar; Dihua Yu; Raphael E Pollock; Roger R Reddel
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Telomerase activity in human brain tumours.

Authors:  L A Langford; M A Piatyszek; R Xu; S C Schold; J W Shay
Journal:  Lancet       Date:  1995-11-11       Impact factor: 79.321

6.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

8.  The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Authors:  Calin O Marian; Steve K Cho; Brian M McEllin; Elizabeth A Maher; Kimmo J Hatanpaa; Christopher J Madden; Bruce E Mickey; Woodring E Wright; Jerry W Shay; Robert M Bachoo
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

9.  TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.

Authors:  Marc Remke; Vijay Ramaswamy; John Peacock; David J H Shih; Christian Koelsche; Paul A Northcott; Nadia Hill; Florence M G Cavalli; Marcel Kool; Xin Wang; Stephen C Mack; Mark Barszczyk; A Sorana Morrissy; Xiaochong Wu; Sameer Agnihotri; Betty Luu; David T W Jones; Livia Garzia; Adrian M Dubuc; Nataliya Zhukova; Robert Vanner; Johan M Kros; Pim J French; Erwin G Van Meir; Rajeev Vibhakar; Karel Zitterbart; Jennifer A Chan; László Bognár; Almos Klekner; Boleslaw Lach; Shin Jung; Ali G Saad; Linda M Liau; Steffen Albrecht; Massimo Zollo; Michael K Cooper; Reid C Thompson; Oliver O Delattre; Franck Bourdeaut; François F Doz; Miklós Garami; Peter Hauser; Carlos G Carlotti; Timothy E Van Meter; Luca Massimi; Daniel Fults; Scott L Pomeroy; Toshiro Kumabe; Young Shin Ra; Jeffrey R Leonard; Samer K Elbabaa; Jaume Mora; Joshua B Rubin; Yoon-Jae Cho; Roger E McLendon; Darell D Bigner; Charles G Eberhart; Maryam Fouladi; Robert J Wechsler-Reya; Claudia C Faria; Sidney E Croul; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Peter B Dirks; William A Weiss; Ulrich Schüller; Ian F Pollack; Stefan Rutkowski; David Meyronet; Anne Jouvet; Michelle Fèvre-Montange; Nada Jabado; Marta Perek-Polnik; Wieslawa A Grajkowska; Seung-Ki Kim; James T Rutka; David Malkin; Uri Tabori; Stefan M Pfister; Andrey Korshunov; Andreas von Deimling; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2013-10-31       Impact factor: 17.088

10.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Authors:  Yuchen Jiao; Patrick J Killela; Zachary J Reitman; Ahmed B Rasheed; Christopher M Heaphy; Roeland F de Wilde; Fausto J Rodriguez; Sergio Rosemberg; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Chetan Bettegowda; Nishant Agrawal; Eric Lipp; Christopher Pirozzi; Giselle Lopez; Yiping He; Henry Friedman; Allan H Friedman; Gregory J Riggins; Matthias Holdhoff; Peter Burger; Roger McLendon; Darell D Bigner; Bert Vogelstein; Alan K Meeker; Kenneth W Kinzler; Nickolas Papadopoulos; Luis A Diaz; Hai Yan
Journal:  Oncotarget       Date:  2012-07
View more
  7 in total

1.  De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.

Authors:  Brett J Theeler
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

2.  Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.

Authors:  Da Eun Jeong; Seon Rang Woo; Hyun Nam; Do-Hyun Nam; Jae-Ho Lee; Kyeung Min Joo
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

3.  Precision oncology in the age of integrative genomics.

Authors:  Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Nat Biotechnol       Date:  2018-01-10       Impact factor: 54.908

4.  TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.

Authors:  Barbara Heidenreich; P Sivaramakrishna Rachakonda; Ismail Hosen; Florian Volz; Kari Hemminki; Astrid Weyerbrock; Rajiv Kumar
Journal:  Oncotarget       Date:  2015-04-30

5.  Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach.

Authors:  Lei Chen; Tao Huang; Yu-Hang Zhang; Yang Jiang; Mingyue Zheng; Yu-Dong Cai
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

6.  A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas.

Authors:  Weicheng Zheng; Ruolan Zhang; Ziru Huang; Jianpeng Li; Haonan Wu; Yuwei Zhou; Jinwei Zhu; Xianlong Wang
Journal:  Front Mol Biosci       Date:  2022-04-14

7.  Atypical Choroid Plexus Papilloma of the Fourth Ventricle in an Adult: A Case Report.

Authors:  Keshav Goel; Uday Birdi; Simon Menaker; Serguei I Bannykh; Chirag Patel
Journal:  Cureus       Date:  2022-05-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.